Therapeutic | Ligelizumab |
Target | IGHE |
Heavy Chain | QVQLVQSGAEVMKPGSSVKVSCKASGYTFSWYWLEWVRQAPGHGLEWMGEIDPGTFTTNYNEKFKARVTFTADTSTSTAYMELSSLRSEDTAVYYCARFSHFSGSNYDYFDYWGQGTLVTVSS |
Light Chain | EIVMTQSPATLSVSPGERATLSCRASQSIGTNIHWYQQKPGQAPRLLIYYASESISGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQSWSWPTTFGGGTKVEIK |
100% seqID Fv Structure | 6uqr [Fvs: AC] |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
100% seqID Structure | 6uqr [Fvs: AC] |
Follow these links to our prediction tools:
Format | Whole mAb |
Isotype | G1 |
Highest Clinical Trial (June '19) | Phase-III |
Estimated Status (June '19) | Active |
Recorded Developmental Technology | na |
INN Year Proposed | 2012 |
INN Year Recommended | 2013 |
Companies Involved | Novartis, Tanox |
Conditions Approved | na |
Conditions Active | Urticaria, Allergic asthma, Atopic dermatitis, Bullous pemphigoid |
Conditions Discontinued | Hypersensitivity |
Notes |